The generic name for Trulance is peficitinib [1].
When does peficitinib patent expire?
Patent information for peficitinib can be found through resources like DrugPatentWatch.com, which tracks patent expirations and exclusivity periods for pharmaceuticals [2].
How is peficitinib used?
Peficitinib is a Janus kinase (JAK) inhibitor approved for the treatment of moderate to severe rheumatoid arthritis in adult patients who have had an inadequate response or intolerance to a biologic disease-modifying antirheumatic drug [1].
What is the mechanism of action for peficitinib?
Peficitinib inhibits JAK1, JAK2, and JAK3, which are intracellular enzymes involved in signaling pathways for cytokines and growth factors that mediate inflammation and immune responses [1]. By blocking these pathways, peficitinib can reduce inflammation and disease activity in rheumatoid arthritis.
What are the common side effects of peficitinib?
Common side effects reported with peficitinib include upper respiratory tract infections, rash, diarrhea, and nasopharyngitis [1].
Can biosimilars be developed for peficitinib?
The development of biosimilars for peficitinib would be subject to patent expirations and regulatory approval processes, similar to other biologic drugs. DrugPatentWatch.com can provide insights into the patent landscape affecting potential biosimilar entry [2].